{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 87 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'When I do, or if I were to do, the following tasks, I would rate my', 'breathlessness as:', '0', 'None at all', '1', '2', '3', '4', 'Severe', '5', 'Maximal or unable to do because of', 'breathlessness', '11.', 'Dressing', '0', '1', '2', '3', '4', '5', '12.', 'Picking up and straightening', '0', '1', '2', '3', '4', '5', '13.', 'Doing dishes', '0', '1', '2', '3', '4', '5', '14.', 'Sweeping /vacuming', '0', '1', '2', '3', '4', '5', '15.', 'Making bed', '0', '1', '2', '3', '4', '5', '16.', 'Shopping', '0', '1', '2', '3', '4', '5', '17.', 'Doing laundry', '0', '1', '2', '3', '4', '5', '18.', 'Washing car', '0', '1', '2', '3', '4', '5', '19.', 'Mowing lawn', '0', '1', '2', '3', '4', '5', '20.', 'Watering lawn', '0', '1', '2', '3', '4', '5', '21.', 'Sexual activities', '0', '1', '2', '3', '4', '5', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 88 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '0', 'None at all', '1', '2', '3', '4', 'Severe', '5', 'Maximal or unable to do because of', 'breathlessness', 'How much do these limit you in your daily life?', '22.', 'Shortness of breath', '0', '1', '2', '3', '4', '5', '23.', 'Fear of \"hurting myself\" by', 'overexerting', '0', '1', '2', '3', '4', '5', '24. Fear of shortness of breath', '0', '1', '2', '3', '4', '5', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 89 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '10.7', 'LUNG FUNCTION CRITERIA', 'FVC must fulfil the following criteria:', '45% predicted of normal <FVC of predicted normal', 'Predicted normal values will be calculated according to NHANES', 'DLco must fulfil the following criteria:', '30% predicted of normal < DLco corrected for Hb < 80% predicted of normal', 'For predicted normal values, different sites may use different prediction formulas, based on', 'the method used to measure DLco. In any case, the method used must be in compliance with', 'the ATS/ERS guideline on DLco measurements (R06-2002), and the prediction formula', 'appropriate for that method. Raw data (gas mixture, equation used for prediction of normal,', 'further adjustments made if so) must be traced.', 'DLco corrected for haemoglobin (R06-2002):', 'Males: DLco corrected for Hb = DLCO measured X (10.22+Hb) 1.7Hb', 'Females: DLco corrected for Hb = DLCO measured X (9.38+Hb)/ 1.7Hb', 'where Hb is expressed in g dL-1.', 'For decision on inclusion / exclusion, DLco results from visit 1 will be corrected for', 'haemoglobin by the site, if historical data within 30 days is not available.', 'For analysis of the trial data, DLco results from visits 2, 5 and 7 will be corrected for', 'haemoglobin by central data management. This means that the site has to enter the DLco', 'result without haemoglobin correction in the e-CRF, at all visits.', 'The value to be entered in the e-CRF is the mean of the acceptable manoeuvers performed', 'during a test. There should be at least two acceptable tests that meet the repeatability', 'requirement of either being within 3 mL CO (STPD)-min\u00b9 *mmHg\u00b9 (or 1 *kPa-\u00b9', 'of each other or within 10% of the highest value.', 'If highest value was entered at baseline and cannot be corrected retrospectively, the same', 'measurement should be recorded until the 24 week evaluation.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}